Major complications of tibial tuberosity advancement in 1613 dogs.

OBJECTIVES: To report major postoperative complications in 1613 dogs with tibial tuberosity advancement (TTA). STUDY DESIGN: Retrospective case series. SAMPLE POPULATION: Dogs (n = 1613) with cranial cruciate ligament deficiency treated with TTA. METHODS: Medical records of TTAs performed between December 2007-2013 were reviewed for age, sex, weight, contralateral stifle surgery, surgical approach, duration of preoperative lameness, presence of meniscal damage, concurrent patellar luxation and simultaneous bilateral TTA. Major postoperative complications were defined as surgical site infection (SSI) (superficial, deep, or organ/space), implant failure, fracture, patellar luxation, and meniscal tear. RESULTS: Major complications were recorded in 13.4% of cases. Superficial SSI (incisional irritation) was diagnosed in 6.9% cases, requiring only antimicrobial therapy. Other complications included postliminary medial meniscal tear (2% incidence), deep SSI (incisional dehiscence, 1.1%), implant failure (1%), patellar luxation (1.2%), fracture (0.9%), and organ/space SSI (septic arthritis, 0.4%). Dogs with normal menisci were less likely to develop postliminary meniscal tears if the medial meniscus was released at the time of TTA (P < .0001). No association was detected between recorded parameters and complications, although dogs >8 years old approached significance (P = .05) in terms of predisposition to major complications. CONCLUSIONS: Major complications after TTA are uncommon, even in dogs with concurrent patellar luxation or bilateral simultaneous procedures. In spite of its morbidity, medial meniscal release may prevent postliminary meniscal tears.

Clinical Validation of a Novel Quality Management System for Blood Gas, Electrolytes, Metabolites, and CO-Oximetry.

BACKGROUND: Quality management of point-of-care (POC) blood gas testing focuses on verifying instrument accuracy and precision, in addition to performing daily quality control (QC) checks every 8 h and with each patient test (unless internal calibration is verified every 30 min). At the POC, a risk-based approach is suitable to address both systemic and transient sample-specific errors that may negatively impact patient care. METHODS: We evaluated the performance of the GEM® Premier™ 5000 with next generation Intelligent Quality Management 2 (iQM®2) (Instrumentation Laboratory, Bedford, MA), from the analysis of approximately 84,000 patient samples across 4 sites. Continuous iQM2 was compared to intermittent liquid QC, either manual or automated, at 2 sites. Analysis of error flags for patient samples and statistical characteristics of QC processes, including method sigma and average detection time (ADT) for an error, were examined. RESULTS: ADT was approximately 2 min with iQM2 and varied from hours to days with intermittent QC. iQM2 Process Control Solutions (PCS) precision was similar or better (>6 sigma for all analytes) than manual (sigma 3.0 for pO2) or automated internal QC (sigma 1.3 for tHb and sigma 3.3 for pO2). In addition, iQM2 detected errors in ∼1.4% of samples, providing an additional safeguard against reporting erroneous results. CONCLUSIONS: The findings in this study demonstrate excellent performance of the GEM Premier 5000 with iQM2 including >6 sigma precision for all analytes and faster error detection times. These benefits address risk in different phases of testing that are not easily detected by intermittent performance of liquid QC (manual or automated).